Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds
暂无分享,去创建一个
Auguste Genovesio | Jiyeon Jang | Jair L. Siqueira-Neto | A. Genovesio | J. Cechetto | E. Chatelain | J. Siqueira-Neto | T. Christophe | Seunghyun Moon | Jiyeon Jang | Gyongseon Yang | Changbok Lee | L. Freitas-Junior | Ok-Ryul Song | Jiyoun Nam | Jeong‐Hun Sohn | Seunghyun Moon | Lucio H. Freitas-Junior | Ok-Ryul Song | Thierry Christophe | Eric Chatelain | Jonathan Cechetto | Jiyoun Nam | Jeong-Hun Sohn | Hyunrim Oh | Gyongseon Yang | Chang Bok Lee | Hyunrim Oh | Jonathan Cechetto | Auguste Genovesio
[1] H. Murray,et al. Drugs against leishmaniasis: a synergy of technology and partnerships. , 2004, Trends in parasitology.
[2] Heather J Munden,et al. The Genome of the Kinetoplastid Parasite, Leishmania major , 2005, Science.
[3] Ghosh Ak,et al. Effect of berberine chloride on Leishmania donovani. , 1983 .
[4] V. Yardley,et al. Drug sensitivity of Leishmania species: some unresolved problems. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[5] R. Peeling,et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? , 2007, Nature Reviews Microbiology.
[6] John S. Lazo,et al. Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule Screen , 2009, PLoS neglected tropical diseases.
[7] R. Madhubala,et al. Paromomycin: uptake and resistance in Leishmania donovani. , 2009, Molecular and biochemical parasitology.
[8] D. Sereno,et al. Advances and perspectives in Leishmania cell based drug-screening procedures. , 2007, Parasitology international.
[9] R. Neal,et al. The activity of nitrofurazone and furazolidone against Leishmania donovani, L. major and L. enriettii in vitro and in vivo. , 1988, Annals of tropical medicine and parasitology.
[10] S. Brooker,et al. Cutaneous leishmaniasis – Authors' reply , 2008 .
[11] J. Raynes,et al. Activation of p38 Mitogen-Activated Protein Kinase Attenuates Leishmania donovani Infection in Macrophages , 2002, Infection and Immunity.
[12] S. Brooker,et al. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. , 2008, International journal of epidemiology.
[13] A. Ghosh,et al. Effect of berberine chloride on Leishmania donovani. , 1983, The Indian journal of medical research.
[14] John Horton,et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. , 2005, The American journal of tropical medicine and hygiene.
[15] J H Zhang,et al. Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. , 2000, Journal of combinatorial chemistry.
[16] J. Vacus,et al. Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[17] W. de Souza,et al. Antileishmanial Activity of Parthenolide, a Sesquiterpene Lactone Isolated from Tanacetum parthenium , 2005, Antimicrobial Agents and Chemotherapy.
[18] B. W. Penman,et al. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.
[19] R. Brun,et al. Structure-activity study of pentamidine analogues as antiprotozoal agents. , 2009, Journal of medicinal chemistry.
[20] R. Titus,et al. Novel Compounds Active against Leishmania major , 2006, Antimicrobial Agents and Chemotherapy.
[21] K. Kinnamon,et al. The antileishmanial activity of lepidines. , 1978, The American journal of tropical medicine and hygiene.
[22] C. King,et al. Asymmetries of Poverty: Why Global Burden of Disease Valuations Underestimate the Burden of Neglected Tropical Diseases , 2008, PLoS neglected tropical diseases.
[23] Sonu Sundd Singh,et al. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. , 2006, Current drug metabolism.
[24] F. Guengerich,et al. Characterization of Orphan Human Cytochromes P450 , 2007, Drug metabolism reviews.
[25] S. Croft,et al. An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. , 1992, Acta tropica.
[26] S. Sundar,et al. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. , 2005, The American journal of tropical medicine and hygiene.
[27] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[28] P. Desjeux,et al. Estimation of population at risk of infection and number of cases of Leishmaniasis. , 1992, Parasitology today.
[29] Paul Cos,et al. In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences , 2009, Antimicrobial Agents and Chemotherapy.
[30] B. Vion,et al. Cutaneous leishmaniasis , 1990 .
[31] Solomon Nwaka,et al. Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.
[32] D Steverding,et al. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. , 2000, Parasitology international.
[33] Wanis H Ibrahim,et al. Recent advances and controversies in adult cardiopulmonary resuscitation , 2007, Postgraduate Medical Journal.